A5035905541- Systemic Lupus Erythematosus Research
- Atherosclerosis and Cardiovascular Diseases
- Monoclonal and Polyclonal Antibodies Research
- Renal Diseases and Glomerulopathies
- Peripheral Neuropathies and Disorders
- Vasculitis and related conditions
- Rheumatoid Arthritis Research and Therapies
- Cytokine Signaling Pathways and Interactions
- Lipid metabolism and disorders
- Multiple Sclerosis Research Studies
- Systemic Sclerosis and Related Diseases
- Lymphoma Diagnosis and Treatment
- Otitis Media and Relapsing Polychondritis
- Galectins and Cancer Biology
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Extracellular vesicles in disease
- Liver Diseases and Immunity
- Chronic Lymphocytic Leukemia Research
- T-cell and B-cell Immunology
- Sarcoidosis and Beryllium Toxicity Research
- Inflammasome and immune disorders
- Whipple's Disease and Interleukins
- Immune cells in cancer
- Genetic Syndromes and Imprinting
- Cancer-related molecular mechanisms research
National and Kapodistrian University of Athens
2021-2025
University General Hospital Attikon
2020-2024
Biomedical Research Foundation of the Academy of Athens
2022
Objective To obtain real-world data on outcomes of belimumab treatment and respective prognostic factors in patients with systemic lupus erythematosus (SLE). Methods Observational study 188 active SLE (median disease duration 6.2 years, two previous immunosuppressive/biological agents) treated belimumab, who were monitored for SLEDAI-2K, Physician Global Assessment (PGA), LLDAS (lupus low activity state), remission (DORIS/Padua definitions), SELENA-SLEDAI Flare Index, SLICC/ACR damage index...
Systemic lupus erythematosus with antiphospholipid syndrome (SLE-APS) represents a challenging SLE endotype whose molecular basis remains unknown.
Objective Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterised by variable treatment responses. We investigated the transcriptional landscape associated with response and resistance in SLE. Methods Blood was collected from 92 active patients SLE at baseline after 6 months (n=32 paired samples) of cyclophosphamide (n=40), rituximab (n=20), belimumab (n=23), mycophenolate mofetil (n=8) or azathioprine (n=1) subjected to RNA sequencing. The defined Lupus Low...
Peripheral blood monocytes propagate inflammation in systemic lupus erythematosus (SLE). Three major populations of have been recognized namely classical (CM), intermediate (IM) and non-classical (NCM). Herein, we performed a comprehensive transcriptomic, proteomic functional characterization the three peripheral monocytic subsets from active SLE patients healthy individuals. Our data demonstrate extensive molecular disruptions circulating NCM, characterized by enhanced inflammatory features...
The demyelinating syndromes of the central nervous system (CNS) that occur in context systemic lupus erythematosus (SLE) may represent a manifestation neuropsychiatric (NPSLE) or an overlap SLE and multiple sclerosis (MS). differential diagnosis between two entities has important clinical implications because therapeutic management differs.To characterize CNS large cohort as SLE-MS using multidisciplinary approach existing diagnostic (for MS) classification criteria SLE).Patients from...
Abstract Objectives There are limited data regarding health-related quality of life (HRQoL) in patients with ANCA-associated vasculitides (AAVs). We aimed to evaluate the HRQoL AAVs and compare it another chronic inflammatory disease like RA healthy controls (HC). Methods This was a multicentre, cross-sectional study recruited from three tertiary rheumatology clinics. assessed Short Form 36 Health Survey, which included physical mental component summary scores (PCS MCS). Data 1007 HC served...
<h3>Background:</h3> Belimumab has demonstrated disease-modifying effects both in clinical trials and observational studies, however the molecular underpinnings of its their ability to predict early response remain unexplored. <h3>Objectives:</h3> To delineate immunomodulatory belimumab identify potential biomarkers through a longitudinal, in-depth characterization whole blood transcriptome. <h3>Methods:</h3> Whole RNA-sequencing was performed 71 active SLE patients at baseline, 1 6 months...
Belimumab is a putative disease-modifying agent in systemic lupus erythematosus (SLE), yet the molecular underpinnings of its effects and ability to predict early clinical response remain unexplored. To address these, we undertook longitudinal, in-depth blood transcriptome study. RNA-sequencing was performed active SLE patients at baseline following 6 months belimumab treatment (n=45 paired samples). Clinical determined according Responder Index (SRI)-4 Lupus Low Disease Activity State...
Abstract Background Serious infections (SI) are common in patients with ANCA-associated vasculitides (AAV) like granulomatosis polyangiitis (GPA) and microscopic (MPA). Real-life data regarding their incidence predisposing factors—after the introduction of B cell depleting agents—are limited while quantifying risk per treatment modality year disease missing. Here, we aim to describe details factors for SI a contemporary AAV cohort. Methods Multicenter, observational, retrospective study...
<h3>Objective</h3> To discern predictive factors for the development of incident lupus nephritis (LN) in systemic erythematosus (SLE) patients. <h3>Methods</h3> Patients with SLE, according to American College Rheumatology 1997 criteria and/or Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) 2012 criteria, from a mixed prevalent and cohort ('Attikon' cohort) were followed biopsy-proven nephritis. Demographics, clinical characteristics laboratory values at baseline...
Abstract Objectives To discern predictive factors for incident kidney involvement in patients with SLE. Methods Patients SLE from the ‘Attikon’ Lupus cohort were monitored LN, defined by histology and/or classification criteria. Demographic and clinical characteristics at baseline compared against who did not develop LN. LN-free Kaplan–Meier survival curves generated. A multivariate Cox proportional hazards model was used to identify independent predictors of Independent validation performed...
<h3>Background:</h3> Systemic lupus erythematosus (SLE) with antiphospholipid syndrome (APS) represents one of the most challenging endotypes SLE, yet its distinctive molecular basis from non-APS SLE remains elusive. <h3>Objectives:</h3> To comprehensively profile blood transcriptome a large cohort patients who had APS or tested positive for aPL, to advance our understanding and introduce novel therapeutic interventions. <h3>Methods:</h3> We analyzed whole RNA-sequencing data 299 (108...
Background ANCA associated vasculitides (AAVs) are rare, serious forms of vasculitides. There limited data regarding the quality life in patients with AAVs compared to other chronic inflammatory diseases. Objectives The purpose this study was compare between AAV and those a arthritis such as rheumatoid (RA). Methods Multicenter, cross-sectional RA followed three tertiary referral centers. Data from 1007 healthy controls served historic controls. 1 HRQoL assessed Short Form 36 Health Survey...
Background: The lack of pathognomonic features poses a considerable challenge in SLE diagnosis. time from symptom onset to diagnosis has been reported range two six years 1 . Objectives: To document the initial symptoms disease and lapse until its Methods: We examined 438 patients “Attikon” cohort 2 For diagnosis, we used classification criteria (ACR, SLICC, EULAR-ACR) or few cases clinical (n=32, 7.3%). Data were collected using patient interviews, in-person visits medical charts review....
Background: Systemic Lupus Erythematosus (SLE) can first present with severe or critical disease leading to hospitalization. Prompt recognition of the in hospitalized patients may lead early institution treatment and improve outcomes. We have recently developed a clinician-friendly algorithm for SLE diagnosis based on classical clinical serological features [SLE Risk Probability Index (SLERPI)] 1 . Objectives: To determine phenotype diagnosed during hospitalization, interval between...
<h3>Background</h3> The attribution of neuropsychiatric manifestations to systemic lupus erythematosus (SLE) or unrelated causes is often obscure. <h3>Objectives</h3> events (SLE related) other (non-SLE in a large SLE cohort. <h3>Methods</h3> Retrospective study 707 patients from "Attikon" cohort <sup>[1,2]</sup>. Neuropsychiatric were classified as either primary related; attributed using combination multidisciplinary physician judgment with models <sup>[3]</sup>) secondary NPSLE not SLE)...
Background: Targets of therapy and quality care are receiving increased attention in the management SLE, as outlined 2019 update EULAR recommendations for SLE treatment. Objectives: To assess compliance with indicators attainment treatment targets, according to recent recommendations, cohort “Attikon” Rheumatology Unit. Methods: 100 consecutive patients followed at least one year were. A 30 item Quality Indicator Set (QIS) was developed, include laboratory tests diagnosis monitoring,...
Background Belimumab has been introduced in the management of SLE for more than 10 years, however long-term efficacy and safety data are still limited mostly derive from extended phase randomized clinical trials. Objectives To evaluate survival belimumab treatment, reasons treatment cessation associated predictors routine care setting. Methods Multicentre observational study adult patients who were treated with according to physician discretion line EULAR recommendations. Disease activity...
<h3>Purpose</h3> We sought to identify distinct blood transcriptomic signatures of NPSLE patients that could serve as potential biomarkers and therapeutic targets. <h3>Methods</h3> was defined with primary neuropsychiatric events (attributed SLE) using a combination multidisciplinary physician judgment attribution models. Patients without or secondary (neuropsychiatric manifestations not attributed were classified non-NPSLE. Diagnosis SLE established by the Systemic Lupus Erythematosus...